As you stated 11Three deserves more Due Diligence, Further due diligence into the relationship matrix between 11Three and Univec, Inc. Outlines a logical, high-upside business case. While all joint operations remain in a speculative phase, integrating Artificial Intelligence (AI) into this potential framework provides the solid foundation required to scale both entities efficiently.
Until official regulatory paperwork is filed, this scenario remains an unverified, speculative "bull case" built upon the career crossover of Patrick Kelly and Dr. David Dalton, with the foundation of UNVC playing a role.
Dr. David Dalton’s characterization of Univec points directly to an infrastructure- and partnership-heavy business model rather than a consumer-facing retail strategy. UNVC controls vital patient touchpoints, distribution lines, and physical networks via its outpatient behavioral health clinics and specialty pharmaceutical facilities.
11Three controls the proprietary SENDS® nano-emulsion technology designed to drastically enhance the absorption and bioavailability of active compounds. (Pain Patches come to mind)
If private negotiations transition into an executed contract, the structure would materialize as a streamlined Business-to-Business (B2B) alliance: Univec identifies and formulates targeted specialty clinical therapies or non-opioid pain products. Univec pays to license and embed 11Three's SENDS® technology directly inside those formulations, the deploys these high-absorption formulations directly through its existing healthcare networks.
Integrating AI transforms this alliance from a standard laboratory partnership into an exponential technology platform, providing a highly scalable operational foundation: AI machine learning models can computationally simulate thousands of molecular variations in seconds. This allows 11Three to customize its SENDS® technology for Univec's complex medical compounds in weeks rather than months, speeding up the B2B pipeline. AI predictive algorithms can analyze Univec’s electronic health records to track patient treatment outcomes in real time. This generates the hard, mathematical efficacy data required to secure major institutional distribution and insurance contracts.
Keeping in mind UNVC is a publicly traded entity, an operational alliance of this magnitude cannot remain private once executed. A formal licensing contract constitutes a "Material Event", legally requiring a disclosure of the partnership via official financial filings or a public press release.
Securing a robust B2B alliance—backed by an active AI data engine—provides the exact commercial runway 11Three needs to pursue a public market entry via two distinct paths:
Traditional IPO; or a Reverse Merger into an existing public shell corporation or an underperforming public company.
Biggest little Co. no one has ever heard of.
Disclaimer: This document is for informational due diligence purposes only and does not constitute formal investment advice.
PL
Until official regulatory paperwork is filed, this scenario remains an unverified, speculative "bull case" built upon the career crossover of Patrick Kelly and Dr. David Dalton, with the foundation of UNVC playing a role.
Dr. David Dalton’s characterization of Univec points directly to an infrastructure- and partnership-heavy business model rather than a consumer-facing retail strategy. UNVC controls vital patient touchpoints, distribution lines, and physical networks via its outpatient behavioral health clinics and specialty pharmaceutical facilities.
11Three controls the proprietary SENDS® nano-emulsion technology designed to drastically enhance the absorption and bioavailability of active compounds. (Pain Patches come to mind)
If private negotiations transition into an executed contract, the structure would materialize as a streamlined Business-to-Business (B2B) alliance: Univec identifies and formulates targeted specialty clinical therapies or non-opioid pain products. Univec pays to license and embed 11Three's SENDS® technology directly inside those formulations, the deploys these high-absorption formulations directly through its existing healthcare networks.
Integrating AI transforms this alliance from a standard laboratory partnership into an exponential technology platform, providing a highly scalable operational foundation: AI machine learning models can computationally simulate thousands of molecular variations in seconds. This allows 11Three to customize its SENDS® technology for Univec's complex medical compounds in weeks rather than months, speeding up the B2B pipeline. AI predictive algorithms can analyze Univec’s electronic health records to track patient treatment outcomes in real time. This generates the hard, mathematical efficacy data required to secure major institutional distribution and insurance contracts.
Keeping in mind UNVC is a publicly traded entity, an operational alliance of this magnitude cannot remain private once executed. A formal licensing contract constitutes a "Material Event", legally requiring a disclosure of the partnership via official financial filings or a public press release.
Securing a robust B2B alliance—backed by an active AI data engine—provides the exact commercial runway 11Three needs to pursue a public market entry via two distinct paths:
Traditional IPO; or a Reverse Merger into an existing public shell corporation or an underperforming public company.
Biggest little Co. no one has ever heard of.
Disclaimer: This document is for informational due diligence purposes only and does not constitute formal investment advice.
PL
3
